Find out what Sanofi has been up to in 2025, especially as it just closed the Opella deal and is now expanding its pipeline. The post The Sanofi pipeline in 2025: Is the play-to-win strategy working? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is g...| Labiotech.eu
Biotech labs are mining worm chemistry to design medicines that calm the immune system without the risks of live infection.| Freethink
Viruses infect cells with a goal of taking control to churn out new viral copies. Cells have learned to fight back.| The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Tec...
A new study in Nature that finds a gene therapy against HIV given at birth can protect breastfeeding babies from infection with a single dose.| wertheim.scripps.ufl.edu
Dr. Katie Abouzahr, Johnson & Johnson’s new head of late-stage immunology development, draws on her NHS clinical roots and 11 years at Boston Consulting Group to tackle drug R&D’s most complex challenges. Having recently stepped into the role about a month ago, she oversees a portfolio that includes the newly FDA-approved nipocalimab for myasthenia gravis,… The post J&J bets on nipocalimab and oral peptides in immunology appeared first on Drug Discovery and Development.| Drug Discovery and Development
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language… The post Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classifi...| Drug Discovery and Development
One in five of our faculty holds a prestigious R35 Outstanding Investigator Award from the National Institutes of Health.| wertheim.scripps.ufl.edu
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Marta Reguera Gómez, Ph.D., a postdoctoral associate at the UF College of Dentistry, won first place in the postdoctoral poster competition at EPI Research Day 2025.| epi.ufl.edu
Measles virus (MeV) rides its cellular carriages through the blood vessel networks and lymph node stations, spreading far and wide around the body. But after the journey ends, we're stuck paying its fare. How does that happen?| Virology Down Under
AnaptysBio’s investigational drug rosnilimab has delivered promising Phase 2b trial results for moderate-to-severe rheumatoid arthritis.| Drug Discovery and Development
“One of the UK research system’s strengths is having established processes that allow for this review so that we maintain an accurate and robust research record. Promoting and improving this …| For Better Science
Scripps Research awarded doctoral degrees to 59 graduate students, including eight from its partner program based at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, during its 32nd commencement.| wertheim.scripps.ufl.edu
$1B women's health push and RNAi advances mark JPM 2025, with solid tumor therapies gaining momentum| Drug Discovery and Development
The presence or absence of either specific antibodies or antigens in a sample is measured and detected known as ELISA (Enzyme Linked Immunosorbent Assay).| microbialnotes.com
